Trial Status: 
Open to Enrollment
Trial Eligibility: 
  • 18 – 75 years-old
  • Diagnosed with psoriasis via clinician or biopsy
  • Individuals who are NOT currently attempting to get pregnant, are potential candidates for this study
  • At least 3% body surface area currently involved with psoriasis


Trial Description: 

This research study is being done because there is a need for systemic therapies for moderately severe plaque-type psoriasis that are both effective and have minimal side effects.

The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec™ODT for the treatment of acute migraine. However, rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication.

Participation in this study will last approximately 20 weeks (approximately 5 months) and will include approximately 12 study visits. At the end of the study, enrolled subjects will have the opportunity to participate in a 12 week open-label extension trial. 

Eligible participants will receive compensation for travel and inconvenience related to this study. Participants will receive a stipend of $50 for each completed study visit and will be offered an additional $100 for two optional skin biopsies, one at the start and end of the study.  Participants can receive a stipend of up to $1,000 for their completion of all 12 study visits and procedures.

Primary Investigator: 
Richard D Granstein, M.D.
Contact 1 Name: 
Jennifer Vu
Contact 2 Name: 
Morgan Lynch
Trial Location: 
Upper East Side - Manhattan
Drugs / Device: 
Drug
Protocol ID: 
2007022368
Study Type: 
Interventional
Sponsor: 
Weill Cornell Medicine
Trial Category: 
Psoriasis
Teaser: 
This research study is being done because there is a need for systemic therapies for moderately severe plaque-type psoriasis that are both effective and have minimal side effects.